Having committed to offering its rotavirus vaccine--Rotavac--for $1 a dose in 2011, Indian vaccine manufacturer Bharat Biotech has now presented positive Phase III data that compares favorably to currently available rotavirus vaccines.
The World Health Organization (WHO) has cleared the way for artemisinin-combination therapy (ACT) manufacturers to use Sanofi's semi-synthetic active ingredient. WHO acceptance comes one month after Sanofi began producing the active as an alternative to plant-derived artemisinin.
What to do with unused drugs has been a flash point in the U.S. Some states want drugmakers to set up recycling programs, an expense they don't want to undertake.
Biotech Dendreon, the maker of prostate cancer vaccine Provenge, continues to struggle with earnings even after undertaking a restructuring program which included unloading one of its manufacturing plants.
Amarin, which has been setting up a global network of contractors for manufacturing its fish oil product Vascepa so it is ready to go when it starts its hard push for the heart drug, has forged two more links in the chain of manufacturing facilities.
When Sanofi bought an 80% stake in Indian vaccinemaker Shantha Biotech in 2009, the talk was of the deal accelerating growth in emerging markets.Things played out a little differently though.
A scandal over toxic drug capsules in China last year brought more unwanted attention to the gap between the country's place in the pharma ingredient world and the ability of its regulators to keep things on the up-and-up.
After a series of high-profile pharmaceutical heists, the U.S. pharma industry made huge strides in thwarting cargo thieves. But losses are again on the rise as thieves are now hitting more vulnerable last-mile deliveries.
The FDA has been fighting assaults on the pharma supply chain on two major fronts: outright counterfeits and foreign-made versions of drugs. Now a hybrid has appeared: an unapproved, foreign version of Allergan's cosmetic treatment Botox in counterfeit packaging
A Lonza plant in the U.S. has been struggling for 18 months to get its manufacturing practices back up to FDA expectations. But the shortcomings are now leading to shortages for one of its key clients.